Pyoderma Gangrenosum

TORONTO and LAS VEGAS, Oct. 2, 2024 /PRNewswire/ -- MolecuLight Inc., the global leader in fluorescence imaging technology for real-time detection of harmful bacteria and digital wound measurement, proudly announces the presentation of 10 clinical posters featuring MolecuLight at the Symposium on Advanced Wound Care (SAWC) Fall 2024. This interdisciplinary educational event aimed at improving patient outcomes takes place from October 2–5, 2024 in Las Vegas, Nevada. It stands as one of the largest multidisciplinary meetings of wound care professionals globally. Continue Reading SAWC Fall featuring MolecuLight In addition to the clinical posters at SAWC Fall 2024, the MolecuLight i:X® and DX™ imaging devices will be available for demonstration in the MolecuLight Booth #431 in the Exhibition Hall. MolecuLight's showing at SAWC Fall spans a range of clinical applications and highlights new device features. These include optimized wound bed preparation ahead of skin grafting and cellular and tissue-based product (CTP) application, automatic digital wound depth measurement for streamlined workflow, thermal imaging to detect and better treat pressure injuries, associating fluorescence signals with diabetic ulcer healing, and other innovative approaches to wound care. "We are thrilled to see such a strong representation of MolecuLight research at SAWC Fall, which demonstrates the ever-growing adoption and support of our device. The 10 clinical posters being presented highlight the continuously expanding body of evidence in support of the implementation of our technology as part of the standard of care for wound infection management as this has proven to enhance patient outcomes," says Anil Amlani, CEO of MolecuLight, Inc. "MolecuLight is a unique technology in the field, with integrated multiple functions that provide clinicians with a global overview of the wounds' evolution, documents their interventions and findings and enriches every patent encounter with highly accurate, point-of-care information about bacterial burden and wound size." The clinical posters featuring the MolecuLight at SAWC Fall 2024 are as follows: Poster CR-001, "Imaging Beyond the Wound Bed: Leveraging Fluorescence Imaging of Non-Biologicals to Enhance Bacterial-Infection Management", presented by Dr. Charles Andersen Poster CR-002, "The New Age of Wound Care: Leveraging the Synergy of Multi-modal Fluorescence and Thermal Imaging", presented by Dr. Charles Andersen Poster CR-020, "Validation of a Digital Automatic-Depth Measurement Feature within a Multi-Modal Wound Imaging Device", presented by Dr. Laura Jones Poster CR-029, "Bacterial fluorescence imaging improves chronic wound biofilm detection over standard clinical assessment and blotting", presented by Dr. Laura Jones Poster CR-063, "Bacterial Fluorescence in the Application of Cellular Tissue Products", presented by Dr. Alisha Oropallo Poster CR-064, "Co-localization of High Bacterial Load with Regions of Pain in Venous Leg Ulcers: Fluorescence Imaging Informs Interventions and Validates Patient Self-Reported Pain", presented by Dr. Alisha Oropallo Poster CS-012, "Advancing Pyoderma Gangrenosum Wound Care Through Fluorescence-Guided Debridement", presented by Dr. Charles Andersen Poster CS-115, "The Interface of Cutting-Edge Technology in Mission Sustained Injuries of U.S. Special Operations", presented by Dr. Charles Andersen Poster CS-151, "The Association of Bacterial Autofluorescence Signals with Healing Outcomes in Diabetic Foot Ulcers", presented by Dr. Stephanie Woelfel Poster CS-157, "Update on pressure ulcer diagnosis and management: Leveraging Fluorescence and Thermal Imaging", presented by Dr. Charles Andersen About MolecuLight The MolecuLight i:X® and DX™ are the only Class II FDA cleared imaging devices for real-time detection of elevated levels of bacteria in wounds, surgical sites, and other injuries. With unmatched clinical evidence including 100+ peer-reviewed publications representing over 3500 patients, their innovative devices empower healthcare providers to target bacterial removal and make informed treatment decisions. By detecting bacteria in its early stages, MolecuLight technology improves infection management for exceptional patient outcomes. The multi-modal MolecuLight devices combine bacterial detection, wound measurement, and imaging capabilities into a single tool, streamlining workflows and improving documentation accuracy. Integrating seamlessly with electronic medical records, MolecuLight empowers clinicians to deliver the highest standard of care while optimizing their workflow. For more information, contact: Hunter Zudans, Director of Marketing, Moleculight Inc., T. 416.542.5507, [email protected] Photo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

JENA, Germany, Sept. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the e-poster presentation of a post hoc analysis of the SHINE Phase 2b study of its first-in-class anti-C5a antibody, vilobelimab, in hidradenitis suppurativa (HS) at the 2024 European Academy of Dermatology and Venereology (EADV) Congress being held in Amsterdam, September 25 – 28, 2024. Camilla Chong, MD, Chief Medical Officer of InflaRx, commented: “This analysis sheds significant light on the role of C5a/C5aR signaling and vilobelimab’s ability to address the underlying inflammation driving hidradenitis suppurativa (HS), including its potential to reduce not only abscesses and nodules, but draining tunnels that remain a significant burden for many patients with this debilitating disease. In addition, we believe exploring additional efficacy parameters for HS in addition to HiSCR (Hidradenitis Suppurativa Clinical Response) could lead to a greater understanding of the disease-modifying potential of C5a inhibitors such as vilobelimab and C5aR inhibitors such as INF904, particularly with regard to reducing draining tunnels.” E-poster: P0063 Vilobelimab demonstrates significant improvement in reduction of draining tunnels, total lesion count, International Hidradenitis Suppurativa Score 4 and the newly introduced modified-HiSCR: a post hoc analysis of the Phase IIb SHINE study Authors Evangelos J. Giamarellos-Bourboulis, Christopher Sayed, Jamie Weisman, Jacek Szepietowski, Falk Bechara, Niels C. Riedemann, Camilla Chong, Hoda Tawfik SHINE was a prospective, randomized, placebo-controlled, double-blind multicenter Phase 2b trial in 177 patients with moderate to severe HS, with results announced in 2019. The post hoc analysis presented at EADV 2024 looked at other important clinical efficacy endpoints and, in particular vilobelimab 1200 mg, which was statistically significant compared to placebo at 16 weeks. Efficacy parameters assessed included the reduction of draining tunnels (dT), reduction of total lesion counts (abscesses + nodules + draining tunnels (ANdT)) and the International Hidradenitis Suppurativa Score 4 (IHS4) compared to placebo. In this post hoc analysis, vilobelimab 1200 mg demonstrated a placebo-adjusted significant reduction in dT, ANdT, and IHS4 of 45.2%, 25.1% and 31.6%, respectively. InflaRx believes this analysis suggests meaningful clinical benefit for vilobelimab in HS. Further, it supports utilizing a modified version of the HiSCR that measures drug activity against all three lesion types with an emphasis on the reduction of dT, a critical manifestation of the disease that greatly impacts patients’ quality of life. About GOHIBIC (vilobelimab) Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, vilobelimab leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism of the innate immune system, which is not the case for molecules blocking C5. In pre-clinical studies, vilobelimab has been shown to control the inflammatory response-driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response. In addition to development in COVID-19, vilobelimab is also being developed for various debilitating or life-threatening inflammatory indications, including pyoderma gangrenosum (PG). In April 2023, the FDA issued the EUA for GOHIBIC (vilobelimab) for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). In January 2024, InflaRx announced the launch of The InflaRx Commitment Program, pursuant to which the cost of GOHIBIC (vilobelimab) will be refunded for up to six (6) administered inpatient doses (the full treatment course) to institutions that meet the eligibility requirements, for patients who were administered GOHIBIC (vilobelimab) in line with its EUA and who died due to COVID-19 in the intensive care unit. The Marketing Authorization Application (MAA) for the treatment of adult patients with SARS-CoV-2 induced septic ARDS receiving IMV or ECMO is under regulatory review by the European Committee for Medicinal Products for Human Use under the centralized procedure, which applies to all 27 member states of the European Union. About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx). Contacts: InflaRx N.V.MC Services AGJan Medina, CFAVice President, Head of Investor RelationsEmail: IR@inflarx.deKatja Arnold, Laurie Doyle, Dr. Regina LutzEmail: inflarx@mc-services.eu Europe: +49 89-210 2280U.S.: +1-339-832-0752 FORWARD-LOOKING STATEMENTSThis press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

Hosted research and development (R&D) event focused on the differentiation of INF904 and its potential in addressing significant unmet needs in inflammation & immunology (I&I)Initiation of a Phase 2a study with INF904 in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by year-end 2024First Phase 2a data readout for INF904 expected in the summer of 2025, with Phase 2b trial initiation expected in 2025Interim analysis for vilobelimab Phase 3 trial in pyoderma gangrenosum (PG) expected in 2025, and by year-end 2024 InflaRx anticipates providing greater precision on this timelineGOHIBIC (vilobelimab) selected for first Biomedical Advanced Research and Development Authority (BARDA)-sponsored clinical trial to evaluate host-directed therapeutics for treating acute respiratory distress syndrome (ARDS)Cash, cash equivalents and marketable securities of €74.6 million, expected to fund operations into 2026 JENA, Germany, Aug. 08, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced financial results for the three and six months ended June 30, 2024, and provided an operating update. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, commented: “InflaRx continued to advance its differentiated pipeline assets that target significant unmet needs and sizable commercial opportunities in immuno-dermatology. By year-end 2024, we expect to initiate a Phase 2a study with INF904 in chronic spontaneous urticaria and hidradenitis suppurativa, marking an important milestone for us in showcasing INF904’s potentially best-in-class clinical profile. InflaRx is also advancing first-in-class vilobelimab in late-stage development for pyoderma gangrenosum, a debilitating condition with no approved therapy in the U.S. or Europe. Furthermore, clinical data presentations and publications during the second quarter, as well as BARDA’s inclusion of vilobelimab in a Phase 2 trial for acute respiratory distress syndrome, additionally support the relevance of this antibody, as well as C5a and C5aR more broadly, in treating inflammatory conditions.” RECENT HIGHLIGHTS AND BUSINESS UPDATE Oral C5aR inhibitor INF904 – An efficient path in developing a pipeline-in-a-product with Phase 2a trial initiation expected in 2024 In early June the company hosted an R&D event focused on INF904 and its potential in addressing significant unmet needs in I&I. A replay of the event, including the associated agenda and slideshow presentation can be found here. InflaRx also previously disclosed it will pursue two initial immuno-dermatology indications with INF904 in a single Phase 2a basket trial that is expected to begin by the end of 2024. The trial will be a multi-center, open-label study dosing 75 patients and evaluating multiple INF904 dosing regimens over 4 weeks of treatment in patients with moderate-to-severe CSU and moderate-to-severe HS, with the goal of generating additional safety and pharmacokinetic (PK) data and showing meaningful clinical benefit. InflaRx believes INF904 could address markets with annual revenue potential of $1 billion or more in each indication. In addition to CSU and HS, InflaRx believes INF904 could address meaningful markets in other immuno-dermatology and in immuno-inflammation indications, including in nephrology, neurology and hematology. While InflaRx intends to focus its resources on its immediate goals addressing CSU and HS, the company continues to assess and monitor the value of pursuing additional areas and applications via potential future collaborations with partners. INF904 and InflaRx at the 19th European Meeting on Complement in Human Diseases (EMCHD) InflaRx will present two posters for INF904 featuring new preclinical data at EMCHD 2024, which is being held in Lübeck, Germany, September 2 – 6, 2024. In addition to two poster presentations, InflaRx representatives will participate in a C5a/C5aR-focused panel discussion as well as speak at a satellite symposium. Vilobelimab in PG – Enrollment ongoing in pivotal Phase 3 trial with interim analysis expected in 2025 InflaRx is conducting a multi-national, randomized, double-blind, placebo-controlled pivotal Phase 3 study of vilobelimab for the treatment of ulcerative PG, a rare, chronic inflammatory form of neutrophilic dermatosis characterized by accumulation of neutrophils in the affected skin areas. The trial has two arms: (1) vilobelimab plus a low dose of corticosteroids tapered over an 8-week period and (2) placebo plus the same dosing of corticosteroids. The primary endpoint of the study is complete closure of the target ulcer at any time up to 26 weeks after initiation of treatment. The study, which dosed its first patient in November 2023, has an adaptive design with an interim analysis blinded for the sponsor and investigators planned upon enrollment of approximately 30 patients (15 per arm). Depending on the results of the interim analysis, expected to occur in 2025, the trial sample size will be adapted, or the trial will be terminated due to futility. Given recent encouraging enrollment trends, InflaRx anticipates providing increased precision on the 2025 timing of this interim analysis by year-end 2024. The total enrollment period is projected to be at least two years, depending on the total trial size after sample size adaptation. Vilobelimab has been granted orphan drug designation for the treatment of PG by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), as well as fast track designation by the FDA. GOHIBIC (vilobelimab) to be included in BARDA-sponsored Phase 2 ARDS clinical trial In June 2024, InflaRx announced that GOHIBIC (vilobelimab) had been selected by the BARDA as one of three host-directed investigational therapies to be assessed in a Phase 2 clinical platform study exploring potential new options for the treatment of ARDS. The multicenter, randomized, double-blind, placebo-controlled trial is expected to begin later this year and to be conducted at approximately 60 sites in the U.S., with a total target enrollment of 600 hospitalized adults with ARDS. The primary endpoint will be all-cause mortality at Day 28. This Phase 2 platform study is expected to inform the design of Phase 3 studies and identify a patient subpopulation most likely to benefit from each of the three drug candidates. GOHIBIC (vilobelimab) combination data presented at ATS 2024 In May 2024, InflaRx announced data presented at the American Thoracic Society (ATS) 2024 International Conference in a poster titled, “Vilobelimab in Combination with Tocilizumab or Baricitinib Dramatically Improves Mortality in Critically Ill COVID-19 Patients”. The data were derived from a post-hoc subgroup analysis of the PANAMO Phase 3 global study, which included a total of 369 patients and was used to support the emergency use authorization (EUA) granted by the FDA in April 2023 for the treatment of critically ill COVID-19 patients. The analysis assessed 28- and 60-day all-cause mortality in the subgroup of patients (n=71) who were treated with the combination of vilobelimab plus tocilizumab or baricitinib versus patients on placebo plus tocilizumab or baricitinib. All patients received standard of care. The point estimate for 28-day all-cause mortality was 6.3% in the vilobelimab plus tocilizumab or baricitinib arm, and 40.9% in the placebo plus tocilizumab or baricitinib arm: this is a significant relative reduction of 84.6% (HR 0.13; 95% CI:0.03-0.56, p=0.006) between the two arms. Day 60 all-cause mortality was 16.4% and 49.3%, respectively (HR 0.25; 95% CI:0.09-0.68, p=0.006), a significant relative reduction. The co-administration of vilobelimab with baricitinib or tocilizumab was not associated with safety concerns. In addition, demographics of these subgroups were generally well-balanced and comparable to the overall study population. Dr. Thomas Taapken, Chief Financial Officer of InflaRx, said: “InflaRx’s efficient use of cash and focused development strategy with INF904 and vilobelimab have provided InflaRx a strong cash runway, allowing us to advance major clinical programs toward their next milestones and to fund operations into 2026.” FINANCIAL HIGHLIGHTS Revenue For the six months ended June 30, 2024, the Company realized revenues from product sales of GOHIBIC (vilobelimab) in the amount of €42 thousand. Revenues reported are sales to end customers (hospitals). Sales to distributors do not constitute revenue for the Company under IFRS 15. All revenues are attributed to sales made in the United States. Cost of sales Cost of sales during the three and six months ended June 30, 2024 primarily consisted of write-downs of short-lived inventories. Sales and marketing expenses Sales and marketing expenses incurred for the six months ended June 30, 2024 increased by €3.0 million compared to the six months ended June 30, 2023. This increase is primarily due to minimal sales and marketing activities incurred during the six months ended June 30, 2023 due to the GOHIBIC EUA approval received in Q2 2023. R&D expenses R&D expenses incurred for the six months ended June 30, 2024 decreased by €8.3 million compared to the six months ended June 30, 2023. This decrease is primarily due to higher third-party expenses incurred during the first half of 2023 in connection with our efforts to develop the commercial manufacturing process and to obtain an EUA for GOHIBIC (vilobelimab). The decrease of third-party expenses is offset by an increase of personnel expenses by €1.2 million. This increase is attributed to higher stock-based compensation expenses. General and administrative expenses General and administrative expenses decreased by €0.3 million to €6.8 million for the six months ended June 30, 2024, from €7.1 million for the six months ended June 30, 2023. Other income Other income for the six months ended June 30, 2024 amounted to €53 thousand (PY: €12.6 million). There was no income from government grants in 2024 due to the end of the grant period on June 30, 2023. Net financial result Net financial result increased by €3.2 million to €4.4 million for the six months ended June 30, 2024, from €1.2 million for the six months ended June 30, 2023. This increase was mainly attributable to a higher foreign exchange result, which increased by €2.9 million. Net loss Net loss for the first six months of 2024 amounted to €23.5 million, compared to €19.3 million in the first six months of 2023. Net cash used in operating activities Net cash used in operating activities for the first six months of 2024 increased to €27.0 million from €21.7 million for the comparable period in 2023. Liquidity and capital resources As of June 30, 2024, InflaRx’s total available funds amounted to €74.6 million, composed of €19.2 million in cash and cash equivalents and €55.4 million in marketable securities. These funds are expected to finance operations into 2026. Additional financial information Additional information regarding these results and other relevant information is included in the notes to the unaudited interim condensed consolidated financial statements as of June 30, 2024, as well as the consolidated financial statements as of and for the year ended December 31, 2023, in “ITEM 18. Financial Statements,” in InflaRx’s annual report on Form 20-F for the year ended December 31, 2023, as filed with the U.S. Securities and Exchange Commission (SEC) on March 21, 2024. InflaRx N.V. and subsidiariesUnaudited condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2024 and 2023 For the three monthsended June 30, For the six monthsended June 30 2024(unaudited) 2023(unaudited) 2024(unaudited) 2023(unaudited) (in €, except for share data) Revenues6,357 — 42,394 — Cost of sales(348,153) — (568,674) — Gross profit(341,796) — (526,280) — Sales and marketing expenses(1,828,628) (276,051) (3,288,167) (276,051)Research and development expenses(10,016,870) (10,919,595) (17,318,680) (25,651,503)General and administrative expenses(3,226,098) (3,540,805) (6,805,249) (7,149,359)Other income16,730 4,882,908 53,023 12,629,096 Other expenses— (2,624) — (3,190)Operating Result(15,396,663) (9,856,168) (27,885,353) (20,451,007)Finance income848,243 1,087,011 1,754,148 1,543,047 Finance expenses(8,732) (5,052) (10,844) (10,580)Foreign exchange result711,411 767,646 2,535,787 (369,664)Other financial result— (195,567) 103,285 2,241 Income taxes— — — — Income (loss) for the period(13,845,741) (8,202,130) (23,502,977) (19,285,963)Other comprehensive income (loss) that may be reclassified to profit or loss in subsequent periods: Exchange differences on translation of foreign currency28,374 (330) 2,836 (17,116)Total comprehensive income (Loss)(13,817,367) (8,202,460) (23,500,141) (19,303,079) Share information (based on income (loss) for the period) Weighted average number of shares outstanding58,883,272 56,985,734 58,883,272 50,912,459 Income (loss) per share (basic/diluted)(0.24) (0.14) (0.40) (0.38) InflaRx N.V. and subsidiariesUnaudited condensed consolidated statements of financial position as of June 30, 2024 and December 31, 2023 June 30, 2024(unaudited) December 31, 2023 (in €)ASSETS Non-current assets Property and equipment272,446 289,577 Right-of-use assets950,070 1,071,666 Intangible assets44,876 68,818 Other assets230,750 257,267 Financial assets237,755 9,052,741 Total non-current assets1,735,897 10,740,069 Current assets Inventories9,644,241 11,367,807 Current other assets4,865,751 4,036,650 Trade receivables23,727 — Tax receivable1,775,404 3,791,564 Other financial assets55,838,699 77,504,518 Cash and cash equivalents19,152,121 12,767,943 Total current assets91,299,943 109,468,483 TOTAL ASSETS93,035,840 120,208,552 EQUITY AND LIABILITIES Equity Issued capital7,065,993 7,065,993 Share premium334,211,338 334,211,338 Other capital reserves43,123,867 40,050,053 Accumulated deficit(309,630,796) (286,127,819)Other components of equity7,385,002 7,382,166 Total equity82,155,403 102,581,730 Non-current liabilities Lease liabilities601,195 745,716 Other liabilities36,877 36,877 Total non-current liabilities638,072 782,593 Current liabilities Trade and other payables8,544,902 11,974,362 Lease liabilities397,475 374,329 Employee benefits1,125,663 1,609,766 Other liabilities174,325 2,885,772 Total current liabilities10,242,365 16,844,229 Total liabilities10,880,437 17,626,822 TOTAL EQUITY AND LIABILITIES93,035,840 120,208,552 InflaRx N.V. and subsidiariesUnaudited condensed consolidated statements of changes in shareholders’ equity for the six months ended June 30, 2024 and 2023 (in €)Issued capital Share premium Other capital reserves Accumulated deficit Other components of equity Total equity Balance as of January 1, 20247,065,993 334,211,338 40,050,053 (286,127,819) 7,382,166 102,581,730 Loss for the period— — — (23,502,977) — (23,502,977)Exchange differences ontranslation of foreign currency— — — — 2,836 2,836 Total comprehensive loss— — — (23,502,977) 2,836 (23,500,141)Equity-settled share-based payments— — 3,073,813 — — 3,073,813 Balance as of June 30, 20247,065,993 334,211,338 43,123,866 (309,630,796) 7,385,002 82,155,403 Balance as of January 1, 20235,364,452 282,552,633 36,635,564 (243,460,290) 7,257,081 88,349,440 Loss for the period— — — (19,285,963) — (19,285,963)Exchange differences ontranslation of foreign currency— — — — (17,116) (17,116)Total comprehensive loss— — — (19,285,963) (17,116) (19,303,079)Issuance of common shares1,687,110 54,796,819 — — — 56,483,929 Transaction costs— (3,360,626) — — — (3,360,626)Equity-settled share-based payments— — 2,239,397 — — 2,239,397 Share options exercised14,431 222,512 — — — 236,943 Balance as of June 30, 20237,065,993 334,211,338 38,874,961 (262,746,253) 7,239,965 124,646,004 InflaRx N.V. and subsidiariesUnaudited condensed consolidated statements of cash flows for the six months ended June 30, 2024 and 2023 For the six monthsended June 30, 2024(unaudited) 2023(unaudited) (in €)Operating activities Loss for the period(23,502,977) (19,285,963)Adjustments for: Depreciation & amortization of property and equipment, right-of-use assets and intangible assets262,932 293,328 Net finance income(4,382,376) (1,165,044)Share-based payment expense3,073,813 2,239,397 Net foreign exchange differences(101,055) (23,953)Changes in: Financial assets from government grants— (4,460,274)Inventories1,723,566 (578,705)Trade receivables(23,727) — Other assets1,213,575 6,295,975 Employee benefits(484,102) (411,774)Other liabilities(2,711,447) 60,443 Liabilities from government grants received— (5,407,634)Trade and other payables(3,429,460) 213,270 Interest received1,369,670 556,068 Interest paid(11,048) (10,777)Net cash used in operating activities(27,002,634) (21,685,642)Investing activities Purchase of intangible assets, property and equipment(28,310) (24,673)Purchase of current financial assets(23,254,210) (83,071,163)Proceeds from the maturity of financial assets56,221,278 55,202,491 Net cash from/(used in) investing activities32,938,758 (27,893,346)Financing activities Proceeds from issuance of common shares— 56,483,929 Transaction costs from issuance of common shares— (3,360,626)Proceeds from exercise of share options— 236,943 Repayment of lease liabilities(193,053) (184,791)Net cash from/(used in) financing activities(193,053) 53,175,455 Net increase/(decrease) in cash and cash equivalents5,743,071 3,596,467 Effect of exchange rate changes on cash and cash equivalents641,107 (345,862)Cash and cash equivalents at beginning of period12,767,943 16,265,355 Cash and cash equivalents at end of period19,152,121 19,515,959 About GOHIBIC (vilobelimab) Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, vilobelimab leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism of the innate immune system, which is not the case for molecules blocking C5. In pre-clinical studies, vilobelimab has been shown to control the inflammatory response-driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response. In addition to development in COVID-19, vilobelimab is also being developed for various debilitating or life-threatening inflammatory indications, including PG. In April 2023, the FDA issued the EUA for GOHIBIC (vilobelimab) for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). In January 2024, InflaRx announced the launch of The InflaRx Commitment Program, pursuant to which the cost of GOHIBIC (vilobelimab) will be refunded for up to six (6) administered inpatient doses (the full treatment course) to institutions that meet the eligibility requirements, for patients who were administered GOHIBIC (vilobelimab) in line with its EUA and who died due to COVID-19 in the intensive care unit. The Marketing Authorization Application (MAA) for the treatment of adult patients with SARS-CoV-2 induced septic ARDS receiving IMV or ECMO is under regulatory review by the European Committee for Medicinal Products for Human Use under the centralized procedure, which applies to all 27 member states of the European Union. About INF904 INF904 is an orally administered, small molecule inhibitor of the C5a receptor that has shown anti-inflammatory therapeutic effects in several pre-clinical disease models. Further, in contrast to the marketed C5aR inhibitor, in vitro experiments demonstrated that INF904 has minimal inhibition of the cytochrome P450 3A4/5 (CYP3A4/5) enzymes, which play an important role in the metabolism of a variety of metabolites and drugs, including glucocorticoids. Reported results from a first-in-human study demonstrated that INF904 is well tolerated in treated subjects and exhibits no safety signals of concern in single doses ranging from 3 mg to 240 mg or multiple doses ranging from 30 mg once per day (QD) to 90 mg twice per day (BID) for 14 days. PK / pharmacodynamic data support best-in-class potential of INF904 with a ≥90% blockade of C5a-induced neutrophil activation achieved over the 14-day dosing period. About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx). Contacts: InflaRx N.V.MC Services AGJan Medina, CFAVice President, Head of Investor RelationsEmail:IR@inflarx.deKatja Arnold, Laurie Doyle, Dr. Regina LutzEmail:inflarx@mc-services.euEurope: +49 89-210 2280U.S.: +1-339-832-0752 FORWARD-LOOKING STATEMENTSThis press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk factors” and “Cautionary statement regarding forward looking statements“ in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.